Studies indicate that modulating enterocyte metabolism might affect whole body glucose homeostasis and the development of diet-induced obesity (DIO). We tested whether enhancing enterocyte fatty acid oxidation (FAO) could protect mice from DIO and impaired glycemic control. To this end, we used mice expressing a mutant form of carnitine palmitoyltransferase-1a (CPT1mt), insensitive to inhibition by malonyl-CoA, in their enterocytes (iCPT1mt) and fed them low-fat control diet (CD) or high-fat diet (HFD) chronically. CPT1mt expression led to an upregulation of FAO in the enterocytes. On CD, iCPT1mt mice had impaired glycemic control and showed concomitant activation of lipogenesis, glycolysis and gluconeogenesis in their enterocytes. On HFD, both iCPT1mt and control mice developed DIO, but iCPT1mt mice showed improved glycemic control and reduced visceral fat mass. Together these data indicate that modulating enterocyte metabolism in iCPT1mt mice affects glycemic control in a body weight-independent, but dietary fat-dependent manner.
Obesity and its related comorbidities, such as type-2-diabetes (T2D), hypertension, and cardiovascular disease, are major global health concerns 1 . With a rise in the consumption of western diets, and with decreasing physical activity, the incidence of obesity is increasing world over. Currently, the only treatments for morbid obesity that lead to sustained weight loss are invasive and costly interventions such as gastric bypass surgery 2 . The success of these surgical procedures comes with several unresolved side effects, including malabsorption of essential micronutrients and early or late post-surgical complications 2 . Interestingly, one of the consistent benefits of bariatric surgeries is improved glycemic control based on a reversal of insulin resistance (IR). These improvements are seen even before any noticeable weight loss 3 . Results from gastric bypass rodent models as well as human patients suggest that these almost immediate improvements are due to functional and/or morphological changes in the small intestine 4, 5 .
Previous pharmacological studies in rodents implicated enhanced fatty acid oxidation (FAO) in the small intestine in the control of eating [6] [7] [8] . We recently reported evidence that a constitutive overexpression of the mitochondrial protein Sirtuin 3 (SIRT3) in mouse enterocytes was associated with enhanced FAO and ketogenesis and reduced fatty acid synthesis in these cells when the mice were fed a fat-rich diet 9 . Interestingly, constitutive enterocyte SIRT3 overexpression had no effect on daily food intake and did not protect the mice from developing diet-induced obesity (DIO), but did protect them from developing IR. SIRT3, however, is a post-translational regulator of several other pathways in addition to FAO, including reactive oxygen species (ROS) scavenging, the tri-carboxylic acid (TCA) cycle, urea cycle and ketogenesis 10 .
To more specifically upregulate FAO in mouse enterocytes, we used the CPT1mt protein, a mutated form of the rat carnitine palmitoyltransferase-1a (CPT1a) enzyme that is insensitive to its endogenous inhibitor malonyl-CoA 11 . Several studies have used the CPT1mt protein in vitro as well as in vivo to enhance mitochondrial FAO flux in target cells or tissues [12] [13] [14] [15] [16] [17] . We crossed the established transgenic mouse line with a floxed STOP cassette preceding the Cpt1mt gene (Cpt1mt fl/fl ) 17 with the Villin-Cre mouse line (Vil-Cre +/− ) 18 to generate mice with a homozygous expression of CPT1mt in the enterocytes (iCPT1mt). We isolated primary enterocytes from the duodenum and jejunum of these mice to test the metabolic flux of these cells. We fed iCPT1mt and Cpt1mt fl/fl mice a low-fat Indirect calorimetry. Measurements were carried out using the Phenomaster/Labmaster metabolic cages (TSE systems). Mice were adapted to single housing in cages similar to the Phenomaster cages for at least one week prior to measurements. Data displayed were collected after additional 2 days of habituation in the system. Animal sacrifice and tissue collection. Mice were food deprived for 2 h prior to sacrifice unless specified otherwise. All animals were sacrificed in the dark phase by decapitation, and trunk blood was collected in tubes containing 0.5 M EDTA. The blood samples were centrifuged at 8,700 g for 10 min at 4 °C, and plasma was collected and stored at −80 °C until required. The intestine and liver were dissected out. Intestinal samples were further processed as described below, and the liver was flash frozen in liquid nitrogen and stored at −80 °C until required. Enterocytes were isolated using a modified protocol described earlier 9,21 using 12.5 mL distritip maxi syringes (#F164120, Gilson) and ice-cold Cell Recovery solution (#354253, Corning). The cells were scraped into ice cold PBS, pelleted and pellets were snap frozen in liquid nitrogen and stored at −80 °C until required.
Primary enterocyte FAO assay. Fifteen to 20-week-old iCPT1mt and CPT1mt fl/fl mice were fasted overnight. Enterocytes were isolated as described above and scraped into ice cold petri dishes containing DMEM (#A1443001, Gibco, ThermoFisher) supplemented with 100 U/mL penicillin and streptomycin (pen-strep), 1 × N-2 supplement, 1 × B-27 supplement, 10 µM Y-27632 and 2 µM N-acetyl cysteine (NAC) and phenol red (basal medium). These cells were then transferred to a 50 mL tube and centrifuged at 500 g for 6 min at room temperature. The cell pellet was resuspended in pre-warmed 0.25% trypsin-EDTA and incubated in a 37 °C, 5% CO 2 incubator for 7 min. An equal volume of soybean trypsin inhibitor (#T6414, SIGMA) containing 20 µM Y-27632 was then added to neutralize trypsin activity. The cells were filtered successively through 100 µ and 40 µ filters. The filtrate was kept on ice, the cells were counted, and an appropriate number of cells was collected in a 2 mL Eppendorf tube, centrifuged at 500 g for 5 min and the resulting pellet was resuspended in ice cold basal medium. An equal volume of ice cold growth factor reduced Matrigel (#354230, Corning) diluted 1:2 in the same medium (to an effective concentration of approximately 5 mg/mL) was added to these cells so that the final concentration of matrigel in the cell suspension was 1:4 (2.5 mg/mL). 250000 (250 K) cells were plated per well in 40 µL of 1:4 matrigel in a regular 96 well cell culture plate. The plate was incubated on ice for 20 min for the cells to settle down through the viscous matrigel, then transferred to a 37 °C, 5% CO 2 incubator for 20 min for the matrigel to solidify. Basal medium was further supplemented with 1.2 × glucose, L-carnitine, fatty acid free BSA, cold palmitic acid and hot ( 3 H-9,10)-palmitic acid, now termed as FAO assay medium. Prewarmed FAO assay medium was added to each well (210 µL medium per well) such that each well now had a total volume of 250 µL of medium with a final (1×) concentration of 2.5 mM glucose, 500 µM L-carnitine, 50 µM fatty acid free BSA, 100 µM cold palmitic acid and 2 µCi/ml of hot ( 3 H-9,10)-palmitic acid. The cells were incubated for 5 h in a 37 °C, 5% CO 2 incubator. Subsequently, 200 µL of medium from each well was transferred into a glass vial and 50 µL of 3 M perchloric acid was added to each vial to stop any metabolic activity. Each vial was closed with a rubber stopper equipped with a hanging well containing a filter paper (1 × 6 cm; #3030-931, Whatman) soaked in 200 µL of water, and then the vials were incubated for 48 h at 37 °C. The filter paper was then carefully transferred into a scintillation vial containing 5 mL of Ultima Gold scintillation fluid (#6013329, Perkin Elmer) along with 100 µL of water used to wash any condensation in the hanging well. The disintegrations per minute were recorded using the 2000CA liquid scintillation analyzer (Tri-Carb). The FAO assay medium containing cold plus hot palmitic acid was used to generate a standard curve using which the FAO flux was calculated from the disintegrations per minute for each sample. Enterocytes from 3 animals were pooled for each genotype (biological replicates) and the n values in the figure legends refer to technical replicates.
Primary enterocyte extracellular flux analysis. Primary enterocytes were subjected to metabolic flux analysis using the extracellular flux analyzer XFe96 (Agilent Seahorse XF technology) subsequently referred to as the "seahorse". Enterocytes, from 15-to 20-week old iCPT1mt and CPT1mt fl/fl mice fasted overnight, were isolated as described above and scraped into a petri dish containing DMEM (#A1443001, Gibco, ThermoFisher) supplemented with 5 mM glucose, 100 U/mL pen-strep, 1 × glutamax, 1 × sodium pyruvate, 1 × N-2 supplement, 1 × B-27 supplement, 10 µM Y-27632 (ROCK inhibitor) and 2 µM NAC. The dissociated and filtered cells were counted, centrifuged at 500 g for 6 min and an appropriate number of cells were resuspended in Krebs-Henseleit Buffer (KHB) containing 111 mM NaCl, 4.7 mM KCl, 1.25 mM CaCl 2 , 2 mM MgSO 4 , 1.2 mM NaH 2 PO 4 supplemented with 100 U/mL pen-strep, 1 × N-2 supplement, 1 × B-27 supplement, 10 µM Y27632 and 2 µM NAC, pH 7.4) further referred to as experimental medium. The cells were plated into the 96 well seahorse cell plate kept on ice so that each well was seeded with 250 K cells in a volume of 20 µL of 1:4 matrigel diluted in experimental medium. The plate was incubated on ice for 20 min and in a 37 °C, 5% CO 2 incubator for 20 min. Pre-warmed experimental medium (160 µL) was then added to each well. The cells were incubated in a CO 2 free incubator at 37 °C for 30 min while the machine was calibrated. Basal oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured by the seahorse analyzer followed by the mitochondrial stress test using appropriate concentrations (see figure legends) of the respiratory poisons Oligomycin (Oligo), Carbonyl cyanide-4-phenylhydrazone (FCCP), Antimycin and Rotenone (Anti + Rot) as indicated. It should be noted that some wells showed a leak from one or more of the B, C or D ports of the cartridge due to capillary action initiated by the medium from the wells touching the ports of the cartridge during the mixing process. We believe that this occurred due to the consistency and thickness of the volume of matrigel in the measurement chamber. These wells were easily identifiable by their decrease in OCR due to oligo or Anti + Rot leak or an increase in OCR due to an FCCP leak even when no compounds were injected into the ports. These wells were eliminated from the analysis. For every parameter we used the average of the three time points measured after the relevant injection/treatment using the equations described below 22 Glycolysis, glycolytic capacity and glycolytic reserve were calculated from the glycolytic stress test using the averages of the three measurements made after the appropriate compound injection as described earlier 23 as well as in the manufacturer's protocol. In brief, glycolytic flux refers to the difference between the mean of measurements after glucose injection and baseline values. Glycolytic capacity refers to the difference between the mean measurements after oligo injection and baseline values, and glycolytic reserve refers to the difference between the mean measurements after oligo injection and after glucose injection. Each well represented a biological replicate of 1, while the n values in the figure legends refer to technical replicates.
Western blotting. Tissue samples were processed for western blotting as described earlier 16 . Briefly, the samples were lysed in RIPA buffer, protein concentrations estimated and denatured in Laemmli buffer containing DTT. Equal amounts of protein samples were run in SDS-PAGE gels and blotted onto PVDF membranes and probed using primary antibodies for CPT1a 24 , HMGCS2 (#sc-33828, Santa Cruz Biotechnology) and β-actin (#A2228, Sigma) and the appropriate HRP-linked secondary antibody. The blots were developed using an in-house chemiluminescence-based detection kit and analyzed using the ImageQuant LAS 4000 mini (GE Health Care). Histology -H&E stain. Two cm pieces of the duodenum and jejunum, and 1 cm 3 liver samples were collected and processed for paraffin embedding and H&E staining as described earlier 9 .
RT-qPCR analysis. RNA was extracted from tissue samples using the Trizol reagent (#15596018, Life Technologies) following the manufacturer's protocol and treated with DNAse (#79254, Quiagen). cDNA was synthesized using the High-Capacity cDNA Reverse Transcription Kit (#4368813, Applied Biosystems) and used for real time quantitative PCR (RT-qPCR) reactions using FAST SYBR green and the Viia7 Real Time PCR system (Applied Biosystems). Each sample was run in triplicate and the best duplicates or triplicates were analyzed using the 2 −∆∆C T method 25 with Ppib as the reference gene 26 . Primers used are listed in Sup Table 1 .
Statistical analysis. All data were analyzed using GraphPad Prism (version 7.0.2) or IBM SPSS statistics (version 23). Outliers were identified using the Grubb's test and removed. Data normality was verified using the Shapiro-Wilk test (when n ≥ 7) and Kolmogorov-Smirnov test (when 5 ≤ n ≤ 6). Parametric data was analyzed using an unpaired Student's t-test (two-tailed) or 2 × 2 factorial parametric analysis of variance followed by Sidak's multiple comparison post hoc test whenever appropriate or a mixed repeated measures ANOVA followed by a simple effects analysis in the case of a significant interaction or a univariate ANCOVA. The nonparametric test (Mann-Whitney) was used when the data did not meet the criteria of normal distribution. Statistical tests used and P-values are mentioned in the figure legends. P-values less than 0.05 were considered significant.
Results iCPT1mt mice show increased CPT1a expression in the intestine, but not in the liver.
Western blot analysis of tissue samples from Cpt1mt fl/fl and iCPT1mt mice fed CD and HFD indicated that the CPT1mt protein was expressed in the enterocytes of the duodenum and jejunum, but not in the liver of iCPT1mt mice (P < 0.0001 for CD duodenum and jejunum; P < 0.05 for HFD duodenum and jejunum) ( Fig. 1A,B ).
Primary enterocytes from iCPT1mt mice have a higher rate of FAO, mitochondrial respiration and glycolysis than Cpt1mt fl/fl control mice. Primary enterocytes isolated from iCPT1mt mice fed standard chow showed an increased flux of palmitate oxidation in the duodenum and jejunum compared to Cpt1mt fl/fl mice (P < 0.05) ( Fig. 2A) . When fed HFD for 3 days, primary enterocytes from the duodenum of iCPT1mt mice showed a lower rate of palmitate oxidation compared to Cpt1mt fl/fl mice (P < 0.001), but the enterocytes from the jejunum of iCPT1mt mice showed an enhanced palmitate oxidation rate compared to controls (P < 0.0001) ( Fig. 2A) . In a mitochondrial stress test with the seahorse analyzer, primary enterocytes isolated from the duodenum and jejunum of iCPT1mt mice fed standard chow showed an increased basal and maximal (P < 0.0001) as well as increased respiration rate linked to ATP synthesis, proton leak (P < 0.001) and increased spare respiratory capacity (P < 0.01) ( Fig. 2B ,C) compared to primary enterocytes from Cpt1mt fl/fl mice. The basal extracellular acidification rate (ECAR) of enterocytes from these chow-fed iCPT1mt mice was also higher than that of cells from Cpt1mt fl/fl controls (P < 0.0001) (Sup Fig. 1A,B ) as well as after the addition of oligomycin (P < 0.01) (Sup Fig. 1A,B ). The addition of 2-deoxyglucose (2-DG), the competitive inhibitor of the enzyme hexokinase (HK1), abrogated the increased maximal respiration as well as the increase in ECAR seen after the addition of glucose, oligomycin and FCCP in these cells (Sup Fig. 1C ). Enterocytes from iCPT1mt mice fed standard chow diet have an increased rate of glycolysis (P < 0.05), glycolytic capacity (P < 0.05) and glycolytic reserve (P < 0.05) (Sup Fig. 1C ,D).
Intestinal CPT1mt expression reduces visceral fat with HFD feeding without affecting body weight gain. HFD feeding increased body weight (significant after 1 week, P < 0.0001), lean body mass (P < 0.0001) and subcutaneous fat mass (P < 0.0001) (microcomputed tomography (CT) measurement after 19 weeks on the diets) compared to CD feeding in all mice irrespective of genotype (Fig. 3A,B ). Total fat mass and visceral fat mass showed an interaction effect (P < 0.05, diet x genotype for both) such that iCPT1mt mice had less visceral fat than Cpt1mt fl/fl mice when fed HFD for 19 weeks (P < 0.05) ( Fig. 3B) .
A morphological analysis of the small intestine of iCPT1mt and Cpt1mt fl/fl mice fed CD or HFD revealed an interaction effect in the villi lengths of their duodenum (P < 0.05, diet x genotype), such that iCPT1mt mice on CD had longer duodenal villi compared to Cpt1mt fl/fl mice (P < 0.05) ( Fig. 3C,D) . HFD feeding led to an increase in the length of villi in the jejunum of all mice (P < 0.01) compared to CD feeding, with no genotype effects ( Fig. 3C,D) . The livers of these mice showed no genotype differences, but all mice on HFD, irrespective of genotype, showed markers of hepatic steatosis compared to CD fed mice (Fig. 3C ).
iCPT1mt mice and Cpt1mt fl/fl control mice show similar energy intake and whole body energy metabolism when fed CD and when switched to HFD. Both iCPT1mt and Cpt1mt fl/fl mice showed a similar decrease in the respiratory exchange ratio (RER) (P < 0.0001) when switched from CD to HFD feeding (Fig. 4A) . No differences were observed in daily energy intake (Fig. 4B ), energy expenditure ( Fig. 4C ) or locomotor activity (Fig. 4D) between the genotypes or on either of the two diets. Intestinal CPT1mt expression compromises glycemic control on the CD, but improves it over time on HFD. An insulin sensitivity test (IST) on iCPT1mt and Cpt1mt fl/fl control mice fed CD or HFD for 12 weeks did not reveal any differences between the two genotypes ( Fig. 5A ). Both HFD-fed iCPT1mt and Cpt1mt fl/fl mice had developed IR as indicated by the increased baseline glucose levels (Fig. 5B ). An oral glucose tolerance test (OGTT) after 13 weeks on the diets revealed that iCPT1mt mice on CD had impaired glucose clearance compared to Cpt1mt fl/fl control mice (P < 0.01, time x genotype) ( Fig. 5C ). A pairwise comparison at each time point showed that iCPT1mt mice had higher circulating glucose levels compared to Cpt1mt fl/fl mice, at every time point measured post glucose gavage (at t = 15 and 120 min, P < 0.05; at t = 30, P < 0.0001; at t = 60 and 90 min, P < 0.01). With HFD feeding, iCPT1mt mice also showed impaired glucose tolerance compared to Cpt1mt fl/fl mice, though with a smaller difference between the two genotypes ( Fig. 5D , time x genotype, P < 0.05), with iCPT1mt mice showing higher circulating glucose levels at 30 min (P < 0.01) and 120 min (P < 0.05) post glucose gavage. After 16 weeks on the diets, mice fed CD continued to show a similar difference, with iCPT1mt mice exhibiting higher levels of circulating glucose in an intraperitoneal GTT (IPGTT) (P < 0.01, time x genotype) ( Fig. 5E ), specifically at 30 (P < 0.05) and 60 min (P < 0.01) post IP glucose injection. HFD-fed iCPT1mt mice, however, showed a reversal of glucose tolerance in the IPGTT. iCPT1mt mice cleared the IP-injected glucose better than Cpt1mt fl/fl mice (P < 0.01, time x genotype) ( Fig. 5F) , with lower glycemia at 30 (P < 0.05), 60 (P < 0.01), 90 (P < 0.01) and 120 min (P < 0.01) post glucose injection. iCPT1mt mice have reduced circulating non-esterified fatty acid (NEFA) levels compared to Cpt1mt fl/fl control mice. An analysis of circulating post-prandial plasma metabolites after 20 weeks on CD or HFD revealed a main effect of diet such that all HFD-fed mice showed lower levels of circulating triacylglycerol (TAG) (P < 0.0001), β-hydroxybutyrate (BHB) (P < 0.05) and NEFA (P < 0.0001) than mice on CD ( Fig. 6A-C) . Plasma NEFA levels also showed a main effect of genotype (P < 0.05), but the post hoc tests did not reveal a significant difference between the genotypes on either diet (Fig. 6C) . Plasma cholesterol as well as plasma glucose levels were higher in all HFD-fed mice than in CD-fed mice, irrespective of genotype (P < 0.0001) ( Fig. 6D-E ).
iCPT1mt mice on CD, but not on HFD, show an upregulation of fatty acid synthesis, glycolysis and gluconeogenic genes in jejunal enterocytes compared to Cpt1mt fl/fl mice. Gene expression
analyses of the jejunal enterocytes of iCPT1mt and Cpt1mt fl/fl mice after 20 weeks on CD and HFD revealed increased expression of genes involved in fatty acid uptake (Fat/cd36) (P < 0.001), fatty acid binding (Fabp1), FAO (Lcad), ketogenesis (Hmgcs2) (P < 0.0001) and malonyl-CoA synthesis (Acc2) (P < 0.0001) in all HFD-fed mice compared to CD-fed mice (Fig. 7, Sup Fig. 2 and Sup Table 1 ). The genes involved in glucose absorption through the apical enterocyte membrane (Sglt1) (P < 0.0001), glycolysis (Hk1) (P < 0.05) and de novo fatty acid synthesis (Acc1) (P < 0.0001) were downregulated in all HFD-fed mice compared to CD-fed mice ( Fig. 7 and Sup Table 1 ). Genes involved in mitochondrial biogenesis were downregulated (Pgc1a) (P < 0.0001), or remained unchanged (Tfam) in all HFD-fed mice compared to CD-fed mice, irrespective of genotype. All iCPT1mt mice showed an upregulation of glycolysis (Hk1), fatty acid binding (Fabp2) (P < 0.05), de novo fatty acid synthesis (Fasn (P < 0.01) and Acc1 (P < 0.001)) compared to Cpt1mt fl/fl mice, and post hoc tests revealed that these effects were significant on the CD (P < 0.05 for Hk1, Fabp2 and Fasn; P < 0.01 for Acc1). The gluconeogenic gene phosphoenolpyruvate carboxykinase 1 (Pepck1) showed an interaction effect in the jejunum (P < 0.01, diet x genotype) such that Pepck1 was upregulated in the CD-fed iCPT1mt mice compared to Cpt1mt fl/fl mice (P < 0.05), with no difference between the genotypes when fed HFD (Fig. 7, Sup Fig. 2 and Sup Table 1 ). The duodenal enterocytes of all HFD-fed mice showed increased expression of Lcad, Hmgcs2, Fat/cd36, Fabp1, Fabp2, Acc2 (P < 0.0001) and Fasn (P < 0.05) and reduced expression of Pgc1a (P < 0.0001) compared to CD-fed mice (Sup Fig. 2 ). The expressions of Pgc1a (P < 0.05) and Acc2 (P < 0.01) were further downregulated in all iCPT1mt mice compared to Cpt1mt fl/fl controls, and a post hoc test showed that this effect was significant for Pgc1a in iCPT1mt mice fed CD (P < 0.05) and for Acc2 in iCPT1mt mice fed HFD (P < 0.01) (Sup Fig. 2 ). Acc1 showed a genotype effect (P < 0.05), but the post hoc comparisons were not significant when compared within each diet (Sup Fig. 2 ). Expression of Sglt1 showed an interaction effect (P < 0.01, diet x genotype) with its levels specifically upregulated in iCPT1mt mice fed CD (P < 0.01) ( Sup Fig. 2) .
The livers of iCPT1mt and Cpt1mt fl/fl mainly showed an upregulation of all the genes tested in HFD-fed mice, compared to those fed CD (P < 0.05 for Hmgcs2, P < 0.01 for Fasn and P < 0.0001 for the other genes), except for Pgc1a and Pepck1, which showed no differences between the genotypes or diets (Sup Fig. 3) . A western blot analysis of these tissue samples showed that protein level of the ketogenic marker HMGCS2 was downregulated in the duodenal and jejunal enterocytes but not in the liver of iCPT1mt mice on CD (P < 0.01 for duodenum, P < 0.05 for jejunum). HMGCS2 protein levels were also downregulated in the jejunal enterocytes (P < 0.05), but not in the duodenal enterocytes or in the liver, of HFD-fed iCPT1mt mice compared to Cpt1mt fl/fl controls (Sup Fig. 4 ).
Discussion
Studies using pharmacological approaches in rodents suggest that metabolic changes in the small intestine can reduce food intake and hence improve DIO 6, 7 . Metabolic changes in the intestine may also contribute to the improvements in glucose homeostasis seen immediately after bariatric surgery in humans and rodents 4 . Here we report that enterocyte CPT1mt expression impaired glycemic control in CD-fed mice, but improved it in HFD-fed mice. These effects were independent of changes in body weight, but were accompanied by increased expressions of genes involved in fatty acid synthesis, glucose uptake, glycolysis and gluconeogenesis, especially in CD-fed iCPT1mt mice.
Using a previously established method, we isolated primary enterocytes from iCPT1mt and Cpt1mt fl/fl mice 9,21 and successfully processed and embedded them in a diluted matrigel matrix such that we could study their metabolic flux in vitro. The increased FAO flux in enterocytes isolated from chow-fed iCPT1mt mice compared to those from Cpt1mt fl/fl mice is consistent with previous studies in which the CPT1mt protein was expressed in different tissues or cell types [12] [13] [14] [15] [16] [17] . Together these results suggest that the enterocytes of iCPT1mt mice are capable of oxidizing more fatty acids than the enterocytes of control Cpt1mt fl/fl mice when fed a low-fat diet. When fed HFD, the jejunal enterocytes of iCPT1mt can enhance their FAO capacity even further. A direct comparison is not possible between the FAO rates of enterocytes from chow and HFD fed mice because they were performed as independent experiments. Visually though, HFD feeding for 3 days seemed to increase the FAO flux of both duodenal and jejunal enterocytes of Cpt1mt fl/fl mice and only the jejunal enterocytes of iCPT1mt mice. This is consistent with previous data from our lab, which showed that the gene expression of FAO enzymes was upregulated in the duodenum and jejunum of wildtype mice fed HFD for 3 days 23 . As for the decrease in the FAO rate in the duodenum of iCPT1mt mice compared to Cpt1mt fl/fl mice, we speculate that the expression of CPT1mt protein may have maximized the FAO capacity of these cells, and they were not able to extend this capacity further at least after 3 days of HFD, but this remains to be tested.
The extracellular flux analysis revealed that pooled duodenal and jejunal enterocytes of chow-fed iCPT1mt mice had an overall increased basal metabolism, in the absence of any added substrate in the medium, compared to enterocytes from Cpt1mt fl/fl mice. Providing glucose increased the rate of glycolysis and mitochondrial respiration in enterocytes from iCPT1mt mice, indicating that their glycolytic as well as oxidative respiration capacity were upregulated compared to enterocytes from Cpt1mt fl/fl mice. It would be interesting to see how HFD feeding would affect these metabolic fluxes.
At the whole body level, we saw no differences in body weight gain between iCPT1mt and Cpt1mt fl/fl mice when fed CD or HFD for up to 20 weeks. This is similar to what we observed in intestinal SIRT3 overexpressing (iSIRT3) mice 9 , suggesting that increasing FAO flux in the enterocytes of mice does not cause a change in body weight gain. A body composition analysis revealed, however, that HFD-fed obese iCPT1mt mice had less visceral fat than Cpt1mt fl/fl mice. Both iCPT1mt and Cpt1mt fl/fl control mice showed similar changes in postprandial circulating TAG, BHB, cholesterol and glucose levels when fed HFD vs CD. These effects were similar to those seen in iSIRT3 mice on HFD and CD, and were consistent with the species-specific effects observed in long-term HFD-fed mice 27, 28 . We saw no genotype differences in energy intake or energy homeostasis when the mice were fed CD or switched to HFD. This was also similar to our findings in iSIRT3 mice 9 , indicating that a constitutive upregulation of FAO in the enterocytes does not affect energy intake or whole body energy metabolism. It would be interesting to see how the energy metabolism in these mice might change after feeding them CD or HFD for several weeks.
Both iCPT1mt and Cpt1mt fl/fl control mice showed similar responses to exogenous insulin after 12 weeks of CD or HFD feeding. iCPT1mt mice however responded differently to exogenous glucose depending on the diet, the route of glucose administration and/or the duration of CD or HFD feeding. These differences could be related to the mode of glucose administration, but may also indicate that adult iCPT1mt mice that may have already been intolerant to glucose, slowly reversed this phenotype when fed HFD chronically. If so, it may explain why the iCPT1mt mice were still comparatively intolerant to exogenous glucose after 13 weeks on HFD, but had reversed this phenotype by 16 weeks. The idea of a biphasic response of glucose intolerance in HFD fed C57Bl6 mice seen after 3 days of HFD feeding and then between 12 to 16 weeks of HFD feeding fits with our idea of a gradual change in glucose tolerance 29 . The reduced visceral fat mass in HFD-fed iCPT1mt mice could also be involved in the improved glucose tolerance, since visceral fat is well known to be associated with the incidence of metabolic syndrome 30 . These results were partly similar and partly different from our findings in iSIRT3 mice. Enterocyte overexpression of SIRT3 had no effect in mice fed CD but did protect them from developing IR and glucose intolerance under conditions of DIO 9 . Expressions of genes for fatty acid binding and fatty acid synthesis were upregulated specifically in iCPT1mt mice compared to Cpt1mt fl/fl controls on CD. This could indicate that CPT1mt expression in the jejunal enterocytes led to increased de novo fatty acid synthesis in these cells, perhaps to funnel fatty acids into the mitochondria for the constitutively active FAO. This assumption is consistent with data from isolated rat hepatocytes expressing the CPT1mt protein. Even in the presence of high glucose and insulin that favor lipogenesis, these cells were able to oxidize de novo synthesized LCFA 12 .
Interestingly, the glycolytic gene Hk1 was upregulated in the jejunal enterocytes of iCPT1mt mice fed CD. This is consistent with the seahorse data from isolated enterocytes, which showed that enterocytes from iCPT1mt mice had a higher rate of glycolysis than enterocytes from Cpt1mt fl/fl mice when provided with glucose. Mitochondrial acetyl-CoA generated via FAO cannot directly leave the mitochondria and fuel fatty acid synthesis. It needs to enter the TCA cycle to generate citrate, which can then leave the mitochondria via the citrate shuttle to fuel de novo lipogenesis 31 . The pyruvate derived from enhanced glycolysis undergoes oxidative decarboxylation, and the resulting Acetyl-CoA also enters the mitochondria to fuel the TCA cycle. When TCA cycle intermediates become limiting, accumulating mitochondrial acetyl-CoA form ketone bodies. In the enterocytes of CD-fed iCPT1mt mice, however, the protein levels of ketogenic HMGCS2 were significantly downregulated. Therefore, we would favor the hypothesis that the accumulating acetyl-CoA could be funneled into the TCA cycle which would eventually fuel lipogenesis. Interestingly, the expression of the gluconeogenic gene Pepck1 was also increased in the jejunal enterocytes of iCPT1mt mice, indicating that these cells were producing glucose. Together these results indicate that the jejunal enterocytes of CD-fed iCPT1mt mice might have developed futile cycles of FAO and lipogenesis, as well as glycolysis and gluconeogenesis.
Concomitantly, in the duodenal enterocytes of CD-fed iCPT1mt mice, we saw an increase in Sglt1 expression. SGLT1 is the glucose transporter in the apical membrane that absorbs glucose from the intestinal lumen, thus supporting the idea of increased glucose absorption. The increased villi length in the duodenum of iCPT1mt mice fed CD as well as the higher levels of blood glucose seen in iCPT1mt mice, 15 minutes after oral, but not IP glucose bolus support the idea of increased glucose absorption from the intestine of iCPT1mt mice fed CD.
On HFD, all mice showed an overall increase in the expressions of genes related to fatty acid uptake, fatty acid binding, FAO and ketogenesis in their duodenal and jejunal enterocytes. Expressions of genes related to glucose absorption, glycolysis and gluconeogenesis were either downregulated in all mice or remained unchanged. Together these results indicate that the futile cycles generated in CD-fed iCPT1mt mice were absent in HFD-fed mice. How these enterocyte metabolic changes might affect whole body glucose homeostasis is still unclear.
In iSIRT3 mice fed HFD, increased ketogenesis in the small intestine was associated with the improved insulin sensitivity and glucose tolerance 9 . In iCPT1mt mice, however, HMGCS2 protein levels were significantly lower and circulating BHB levels were unchanged, indicating that these effects on improved glycemic control were unrelated to ketogenesis. We believe that the increased glucose absorption in the duodenum and the upregulated gluconeogenesis in the jejunum might contribute to the reduced glucose tolerance seen in iCPT1mt mice fed CD. Unlike hepatic gluconeogenesis that is inhibited by insulin, intestinal gluconeogenesis is known to be enhanced in the post absorptive period 32 . The enhanced intestinal gluconeogenesis supposedly provides more glucose for hepatic portal vein glucose sensors that may signal the brain to inhibit eating as reviewed in 33 . Perhaps the higher glucose levels observed in the OGTT and IPGTT are the result of substantially enhanced glucose absorption and/ or gluconeogenesis in the enterocytes of iCPT1mt mice. Another possible explanation is that the permanently enhanced gluconeogenesis and glycolysis in the enterocytes of iCPT1mt mice fed CD limits their capacity to utilize large oral or intraperitoneal loads of glucose properly, leading to impaired glycemic control. Data from rodent models show that gluconeogenesis in the gut can contribute anywhere from 5 to 25% of whole body endogenous glucose production depending on the diet as reviewed in 34 . Mice with a liver specific or liver and intestinal specific knock out of the gluconeogenic gene glucose-6-phosphatase, catalytic subunit (G6pc) showed that in the absence of hepatic gluconeogenesis, intestinal gluconeogenesis is essential to maintain physiological levels of blood glycemia 35 . Together these data indicate that changes in enterocyte metabolism can contribute to and influence systemic glucose concentrations substantially, which supports our idea that enterocyte gluconeogenesis is capable of contributing to the glycemic dysregulation we see in iCPT1mt mice.
Perhaps on HFD, iCPT1mt mice have enough LCFA and carbohydrate intermediates to fuel the constitutive upregulation of FAO and the TCA cycle and therefore do not need a massive upregulation of glucose absorption or gluconeogenesis to fuel the de novo synthesis of fatty acids. The constitutive upregulation of FAO under these conditions could slowly reverse the adverse effects seen under CD fed conditions. It would be interesting to see whether iCPT1mt mice might be prevented from developing DIO and/or impaired glycemia if they were directly weaned onto the HFD. Consistent with this idea hepatic CPT1mt expression was able to prevent the development of DIO and IR in adult mice fed HFHS diet after the expression of CPT1mt using an adeno-associated virus 14 . Also both hepatic and skeletal muscle expressions of CPT1mt were able to reverse already established IR and impaired glycemia in DIO mouse models without affecting body weight 15, 17 . In fact, these studies did not show any adverse effects of CPT1mt expression in mice fed standard chow. The main difference between these mouse SciEnTific REpoRtS | (2018) 8:10818 | DOI:10.1038/s41598-018-29139-6 models and our intestinal transgenic mice, other than the obvious difference in the organs we targeted, is that our mice express CPT1mt constitutively from embryonic development, whereas in these other models the CPT1mt expression was induced in adulthood. An inducible Villin-Cre model, in which we could specifically express CPT1mt in the mouse enterocytes in adulthood, might provide a clearer picture to whether an upregulation of enterocyte FAO would protect from the development of DIO and IR, without the negative effects seen on CD.
The declining slope in the OCR of the enterocytes seen in the mitochondrial stress test was most likely due to a decrease in cell viability over time. Previous studies with intestinal crypts, organoids or intestinal stem cells in the seahorse also showed similar declines in the OCR over time 36, 37 . We believe that this was a drawback of embedding primary enterocytes in a 3D layer of diluted matrigel. We would like to emphasize, however, that the present study represents the first successful attempt to analyze the bioenergetics of live primary enterocytes from adult rodents. As epithelial cells, enterocytes are notoriously difficult to culture alive and especially as single cells. In our attempts to culture these cells, we performed several trial experiments with different cell surface attachment protocols, all of which led to steep declines in the OCR of the enterocytes. The method of embedding the cells in matrigel was the only one that worked and gave a consistently, but comparatively slowly and similarly decreasing slope in every experiment. We also tested different dilutions of matrigel to determine the best conditions under which we were able to achieve a consistent range of OCR as well as a consistent slope.
In sum, these results show that persistent changes in mouse enterocyte FAO do not influence daily energy intake or energy homeostasis and body weight, but affect whole body glucose homeostasis under different dietary conditions. Further studies should try to elucidate the exact mechanism of these effects and dissociate the contribution of the molecular and metabolic changes in the gut versus other organs.
